Serb Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, reported that Serb has acquired exclusive U.S. rights to the ticagrelor reversal agent bentracimab from SFJ. Bentracimab is a novel, monoclonal antibody fragment designed to reverse the antiplatelet activity of ticagrelor. Ticagrelor, marketed by AstraZeneca as Brilinta, is a reversible oral P2Y12 platelet inhibitor for patients who have suffered a heart attack or strok...